ReviewAnatolian journal of cardiology2026
Pathophysiological Insights and Prognostic Value of the Triglyceride-Glucose Index in Patients with Chronic Total Occlusion.
Review in Anatolian journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Triglyceride-glucose index and short-term mortality of adult patients with sepsis: a meta-analysis.Frontiers in endocrinology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The triglyceride-glucose (TyG) index is a surrogate marker of insulin resistance (IR) asso-ciated with atherosclerosis, endothelial dysfunction, and cardiovascular disease (CVD). Chronic total occlusion (CTO) presents major clinical challenges, especially in patients undergoing percutaneous coronary intervention (PCI). This narrative review explores the role of the TyG index in predicting CTO development and adverse cardiovascu-lar outcomes. A literature review of studies assessing the association between the TyG index and CTO, PCI outcomes, and contrast-induced nephropathy (CIN) was conducted. Pathophysiological mechanisms linking IR, TyG, and CTO progression were evaluated, and the predictive utility of the TyG index in risk stratification and post-PCI complica-tions was analyzed. Multiple studies show that a higher TyG index is strongly associated with increased CTO risk, poor collateral circulation, CIN, and adverse outcomes after PCI. Elevated TyG values were independently predictive of impaired collateral formation in diabetic and non-diabetic patients, with stronger effects in metabolically vulnerable subgroups. Individuals with higher TyG levels had a greater likelihood of developing CIN, with analyses confirming its role as an independent predictor. Long-term prognosis in CTO patients was also worse with elevated TyG, with higher rates of major adverse car-diovascular events. The TyG index demonstrated consistent predictive capability com-pared with other metabolic markers, supporting its potential as a low-cost tool for risk stratification. The TyG index is a cost-effective biomarker for predicting adverse out-comes in CTO patients. Its incorporation into clinical assessment may improve early risk identification and support individualized PCI planning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.